Cancer Res Treat.  2004 Jun;36(3):187-191.

Expression of Cyclooxygenase (COX)-2 as a Prognostic Factor in Nasopharyngeal Cancer

• Kim K
• Wu HG
• Park SW
• Kim CJ
• Park CI

Abstract

PURPOSE
To evaluate the relationship between treatment failure and COX-2 expression in nasopharyngeal cancer patients treated with chemotherapy and radiotherapy.
MATERIALS AND METHODS
The subjects of this study were 22 nasopharyngeal cancer patients. The patients were treated with neoadjuvant chemotherapy, followed by radiotherapy, or with radiotherapy alone. The formalin- fixed, paraffin- embedded tissues of 11 patients who developed a locoregional recurrence (n=7) or distant metastasis (n=4) were compared with those of 11 disease free patients. Prognostic factors, including histological type, stage, radiation dose and chemotherapy, were well balanced between the two groups. The COX-2 expression was determined immunohistochemically.
RESULTS
COX-2 expression was stronger in the patients with a locoregional recurrence or distant metastasis than in those free of disease. The COX-2 distribution scores of the control group were as follows: 0 in 7, 1 in 2 and 2 in 2 patients. In the recurrence group, the scores were as follows; 0 in 3, 1 in 1, 2 in 2 and 3 in 5 patients. COX-2 expression was shown to have a statistically significant influence on the treatment failure by the Mann-Whitney U test (p=0.024) and Mantel-Haenszel Chi-Square test (p=0.018). It also significantly influenced the treatment failure when an analysis was performed within patients with a undifferentiated histology (p=0.039 by the Mann- Whitney U test, p=0.037 by the Mantel-Haenszel Chi- Square test).
CONCLUSION
COX-2 expression is believed to be one of the important factors associated with a locoregional recurrence or distant metastasis.

Keyword

Cyclooxygenase-2; Radiotherapy; Nasopharyngeal cancer; Prognostic factor

MeSH Terms

Cyclooxygenase 2
Drug Therapy
Humans
Nasopharyngeal Neoplasms*
Neoplasm Metastasis
Prostaglandin-Endoperoxide Synthases*
Radiotherapy
Recurrence
Treatment Failure
Cyclooxygenase 2
Prostaglandin-Endoperoxide Synthases

Figure

• 

  Fig. 1 The examples of COX-2 staining in an undifferentiated carcinoma of the nasopharynx. (A) Negative for COX-2 staining (COX-2 score 0)(original magnification ×200). (B) Strongly positive cytoplasmic staining (COX-2 score 3)(original magnification ×200).

Reference

1. International Nasopharyngeal Cancer Study Group. Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV undifferentiated nasopharyngeal carcinoma: A positive effect on progression-free survival. Int J Radiat Oncol Biol Phys. 1996; 35:463–469. PMID: 8655368.

2. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, Ensley JF. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized intergroup study 0099. J Clin Oncol. 1998; 16:1310–1317. PMID: 9552031.

3. Gallo OG, Masini EM, Bianchi B, Bruschini L, Paglierani M, Franchi A. Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma. Human Path. 2002; 33:708–714. PMID: 12196922.

4. Lin DT, Subbaramaiah K, Shah JP, Andrew JD, Jay OB. Cyclooxygenase-2: A novel molecular target for the prevention and treatment of head and neck cancer. Head Neck. 2002; 24:792–799. PMID: 12203806.

5. Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, Edelstein D, Soslow RA, Koki AT, Woerner BM, Masferrer JL, Dannenberg AJ. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of head and neck. Cancer Res. 1999; 59:991–994. PMID: 10070952.

6. Kang HJ, Gong G, Jang SJ, Jung PJ, Park CK. Expression of cyclooxygenase-2 in human breast carcinoma: relevance to tumor angiogenesis and expression of estrogen receptor. Cancer Res Treat. 2001; 33:286–295.

7. Chae SW, Sohn JH, Shin HS, Park YE. Expression of cyclooxygenase-2 protein in gastric carcinogenesis. Cancer Res Treat. 2002; 34:252–257.

8. Chae SW, Sohn JH, Kim EJ, Cho EY, Lee BH. Expression of cyclooxygenase-2 and tumor microvessel density in colorectal cancer. Cancer Res Treat. 2003; 35:400–406.

9. Khuri FR, Wu H, Lee JJ, Kemp BL, Lotan R, Lippman SM, Feng L, Hong WK, Xu XC. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res. 2001; 7:861–867. PMID: 11309334.

10. Shamma A, Yamamoto H, Doki Y, Okami J, Kondo M, Fujiwara Y, Yano M, Inoue M, Matsuura N, Shiozaki H, Monden M. Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus. Clin Cancer Res. 2000; 6:1229–1238. PMID: 10778945.

11. Lim HY, Joo HJ, Choi JH, Yi JW, Yang MS, Cho DY, Kim HS, Nam DK, Lee KB, Kim HC. Increased expression of cyclooxygenase-2 protein in human gastric cancer. Clin Cancer Res. 2000; 6:519–525. PMID: 10690533.

12. Sheehan KM, Sheahan K, O'Donoghue DP, MacSweeney F, Conroy RM, Fitzgerald DJ, Murray FE. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA. 1999; 282:1254–1257. PMID: 10517428.

13. Kim HJ, Wu HG, Park IA, Ha SW. High cyclooxygenase-2 expression is related with distant metastasis in cervical cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2003; 55:16–20. PMID: 12504031.

14. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, Speizer FE. Aspirin and the risk of colorectal cancer in women. N Engl J Med. 1995; 333:609–614. PMID: 7637720.

15. Funkhouser EM, Sharp GB. Aspirin and reduced risk of esophageal carcinoma. Cancer. 1995; 76:1116–1119. PMID: 8630885.

16. McCormick DL, Madigan MJ, Moon RC. Modulation of rat mammary carcinogenesis by indomethacin. Cancer Res. 1985; 45L:1803–1808. PMID: 3919946.

17. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, Offerhaus GJA. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993; 328:1313–1316. PMID: 8385741.

18. Hosomi Y, Yokose T, Hirose Y, Nakajima R, Nagai K, Nishiwaki Y, Ochiai A. Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer. 2000; 30:73–81. PMID: 11086200.

19. Souza RF, Shewmake K, Beer DG, Cryer B, Spechler SJ. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res. 2000; 60:5767–5772. PMID: 11059772.

20. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, Taketo MM. Suppression of Intestinal Polyposis in Apc^Δ716 Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2). Cell. 1996; 87:803–809. PMID: 8945508.

21. Nathan CO, Leskov IL, Lin M, Abreo FW, Shi R, Hartman GH, Glass J. COX-2 expression in dysplasia of the head and neck: Correlation with elF4E. Cancer. 2001; 92:1888–1895. PMID: 11745262.

22. Pyo H, Choy H, Amorino GP, Kim JS, Cao Q, Hercules SK, DuBois RN. A selective cyclooxygenease-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin Cancer Res. 2001; 7:2998–3005. PMID: 11595687.

23. Kishi K, Peterson S, Peterson C, Hunter N, Mason K, Masferrer JL, Tofilon PJ, Milas L. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res. 2000; 60:1326–1331. PMID: 10728694.

24. Lee DW, Sung MW, Park SW, Seong WJ, Roh JL, Park B, Heo DS, Kim KH. Increased cyclooxygenase-2 expression in human squamous cell carcinomas of the head and neck and inhibition of proliferation by nonsteroidal anti-inflammatory drugs. Anticancer Res. 2002; 22:2089–2096. PMID: 12174888.